接种疫苗后的 COVID-19 在多发性硬化症或视神经脊髓炎患者中的表现。
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
机构信息
Assistance Publique des Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Neuroscience Clinical Investigation Center, Paris Brain Institute, Sorbonne Université, Paris, France.
Service de Neurologie and CIC INSERM 1434, CHU de Strasbourg, Strasbourg, France.
出版信息
Mult Scler. 2022 Jun;28(7):1155-1159. doi: 10.1177/13524585211049737. Epub 2021 Dec 21.
INTRODUCTION
Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry.
CASE SERIES
We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild.
DISCUSSION
These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.
简介
最近的研究表明，抗 CD20 和芬戈利莫德可能与 COVID-19 疫苗接种后基于刺突蛋白的免疫球蛋白 G 反应降低有关。我们使用 COVISEP 登记处评估了多发性硬化症 (MS) 和视神经脊髓炎 (NMO) 患者尽管接种了疫苗，但 COVID-19 是否仍会发生。
病例系列
我们报告了 18 例在接受两剂 BNT162b2 疫苗接种后发生的 COVID-19 病例，其中 13 例接受了抗 CD20 治疗，4 例接受了芬戈利莫德治疗。COVID-19 严重程度为轻度。
讨论
这些结果加强了建议对接受抗 CD20 治疗的患者进行第三次 COVID-19 疫苗接种，并强调需要对 MS 和 NMO 患者的 COVID-19 疫苗有效性进行前瞻性临床和生物学研究。
Zotero 插件